| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2875
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
1997-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_387d517b068ff8662673f40877429ed2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0dc71fbca86370a8e7305f1dc4ae882b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff9769f3a39b2d3fbb5595c6f800db2c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50980737bd5162e1866e07b0767ee669
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_43179cfe48c411414152aa589fffbf6b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_510ca2dd56aa97826a66148993c66dae |
| publicationDate |
2002-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1186300-A1 |
| titleOfInvention |
Pharmaceutical compositions useful for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways |
| abstract |
The present invention provides pharmaceutical compositions useful for inhibiting an immune responsenand for inhibiting rejection of transplanted tissues. This inhibition comprises preventing annendogenous molecule on a cell selected from the group consisting of gp39 and CD40 antigens fromnbinding its endogenous ligand and preventing an endogenous molecule on a cell selected from thengroup consisting of CTLA4, CD28, and B7 antigens from binding its endogenous ligand. Thenprevention of such molecules from binding their ligand thereby blocks two independent signalnpathways and inhibits the immune response resulting in transplanted tissue rejection. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10143748-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10307481-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8333966-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7754209-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7754208-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9101609-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8106161-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9005612-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8147835-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11352426-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8853366-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8188237-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7829084-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9834589-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8197810-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8409577-B2 |
| priorityDate |
1996-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |